Mabion commences cancer drug clinical trial
MabiobCD20 is a monoclonal antibody used to treat blood cancer, lymphomas and leukemias. The clinical program will involve 600-700 patients and will last approximately two years. Mabion president
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.